We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

68 hedge funds and large institutions have $185M invested in CytomX Therapeutics in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 13

46.31% more ownership

Funds ownership: 0% → 46.31% (+46%)

10% more funds holding

Funds holding: 62 → 68 (+6)

40% less capital invested

Capital invested by funds: $308M → $185M (-$123M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
14
Increased
24
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$11.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.44M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M
4
BFA
BlackRock Fund Advisors
California
+$1.1M
5
Morgan Stanley
Morgan Stanley
New York
+$715K

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$3.89M
2
BI
BVF Inc
California
-$448K
3
ROTUOC
Regents of the University of California
California
-$287K
4
Neuberger Berman Group
Neuberger Berman Group
New York
-$224K
5
RG
Redmile Group
California
-$214K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$1M +$1.1M +91,200 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$955K +$32.7K +2,698 +3%
BIM
28
BlackRock Investment Management
Delaware
$847K +$6K +495 +0.6%
SIM
29
Spark Investment Management
New York
$733K +$519K +42,796 +179%
TCIM
30
TIAA CREF Investment Management
New York
$724K -$2.25K -186 -0.3%
VM
31
VHCP Management
New York
$706K – – –
Morgan Stanley
32
Morgan Stanley
New York
$701K +$715K +59,041 +1,247%
VIA
33
Vident Investment Advisory
Georgia
$695K -$50K -4,124 -6%
Millennium Management
34
Millennium Management
New York
$588K +$648K +53,470 New
ROTUOC
35
Regents of the University of California
California
$524K -$287K -23,700 -33%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$462K -$13.3K -1,100 -3%
TA
37
Teachers Advisors
New York
$384K +$26.8K +2,209 +7%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$365K +$402K +33,186 New
JP Morgan Chase
39
JP Morgan Chase
New York
$313K +$346K +28,517 New
OAM
40
Oxford Asset Management
United Kingdom
$271K +$299K +24,670 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$247K – – –
Russell Investments Group
42
Russell Investments Group
United Kingdom
$243K +$265K +21,842 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$231K +$46.2K +3,812 +22%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$230K – – –
Citigroup
45
Citigroup
New York
$227K +$229K +18,875 +1,059%
MLICM
46
Metropolitan Life Insurance Company (MetLife)
New York
$189K – – –
TI
47
Trexquant Investment
Connecticut
$186K +$205K +16,900 New
Squarepoint
48
Squarepoint
New York
$180K +$198K +16,360 New
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$169K -$303 -25 -0.2%
Wells Fargo
50
Wells Fargo
California
$161K +$83.2K +6,869 +88%
1
2
3

CTMX Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2016, worth a combined $185M — down 40% from $308M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new CTMX positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 13 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $11.2M. The largest seller was BlackRock Advisors, cutting an estimated $3.89M.

  • 68 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2016, up from 62 in Q3 2016.
  • Funds reported $185M of CytomX Therapeutics stock for Q4 2016, down 40% quarter-over-quarter.
  • 14 funds opened new CytomX Therapeutics positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest CytomX Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $11.2M added.
  • The largest CytomX Therapeutics seller in Q4 2016 was BlackRock Advisors, an estimated $3.89M sold.

Based on aggregated 13F filings for Q4 2016.